http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102977207-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_087529263bff949805089feca5279b35 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-81 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36 |
| filingDate | 2012-12-14^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-09-10^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d6ab80b8365ed056cafaaf64e09162a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3abecfe37c8959c66c40331684b9e0d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cccc2bcf58179c41d7afaf90bb5b19a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d488452f9ec6d44bd940b2c5a7307e92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfa0d0009e6e42a66a58c235ca2f20fa |
| publicationDate | 2014-09-10^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102977207-B |
| titleOfInvention | Method for preparing antithrombin |
| abstract | The invention provides a method for preparing antithrombin, which comprises the following steps of: (a) precipitation and dissolution; (b) PEG precipitation; (c) virus inactivation; (e) demodulation; (h) adsorption of residual heparin; (i) virus inactivation; and (j) bacterium removal sub-packing and freeze-drying. Through the invention, the hard silica gel matrix (HeparinHyperD) with higher chemical stability is subjected to heparin affinity chromatography; the matrix has better ability against alkali resistance, and is more suitable for needs of industrial production; and the inventor improves the purification technology and the virus inactivation removal and conducts organic combination to expect deep comprehensive utilization of blood plasma and improve the effectiveness and safety of the AT-III preparation, thereby providing a new option to clinical treatment. |
| priorityDate | 2012-12-14^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 63 of 63.